New Functional Genomic Approaches in Human Cancer Models
CRISPR (which stands for “Clustered Regularly Interspaced Short Palindromic Repeat”) is a novel gene-editing technology that allows cancer researchers and drug developers to modify, delete, or correct a specific area of DNA in order to treat cancer and other diseases. New York University’s Dr. Neville Sanjana and his lab have developed CRISPR screening in numerous ways, thereby expanding the potential of the CRISPR technology for fundamental genomic discovery, gene regulation, and transformative therapeutics (i.e., cancer immunotherapy).
Attend Dr. Sanjana’s webinar to learn more about his lab’s work, including their recent development of the first RNA-targeting CRISPR screens in melanoma (the most serious type of skin cancer) and combined CRISPR perturbations of chromatin modifiers with single-cell measurements of chromatin accessibility.
NCI’s Center for Cancer Research hosts the Bioinformatics Training and Education Program (BTEP) Distinguished Speakers Seminar Series. If you’re an individual with a disability who needs reasonable accommodations to participate in this event, please contact Amy Stonelake at least 5 business days before the event.
Dr. Sanjana is a core faculty member at the New York Genome Center. He holds a joint appointment as assistant professor in the department of biology at New York University (NYU) and is an assistant professor of neuroscience and physiology at the NYU School of Medicine.